Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Boehringer, Ablynx target Alzheimer's

January 15, 2007 | A version of this story appeared in Volume 85, Issue 3

Boehringer Ingelheim and Ablynx have entered an R&D and license agreement aimed at new therapies for Alzheimer's disease based on Ablynx's Nanobodies therapeutic proteins. According to Ablynx, Nanobodies cross the blood-brain barrier more readily than conventional antibodies do. Boehringer Ingelheim will be responsible for the development and commercialization of any products resulting from the deal, which is said to be worth up to $265 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.